Pfizer settles Zantac cancer lawsuits for $250 million

The following is from The Vaccine Reaction.

Pfizer, Inc., the largest pharmaceutical corporation in the world marketing drugs and vaccines, has agreed to pay between $200 to $250 million to settle more than 10,000 lawsuits filed in the United States related to cancer risks associated with its over-the-counter heartburn drug Zantac (also known as ranitidine).

The acid reflux drug was discontinued in U.S. in 2020 after a cancer-causing substance known as N-Nitrosodimethylamine (NDMA) was found in samples.

The French pharmaceutical company Sanofi SA acquired Zantac in 2017. Prior to that, Pfizer and other companies, such as the UK’s GlaxoSmithKline (GSK), owned rights to market the anti-acid drug.

The U.S. Food and Drug Administration (FDA) licensed Zantac in 1983 and by 1988 it had become the world’s best selling drug.

After NDMA was found in samples of Zantac, in 2020 the FDA asked drugmakers to pull Zantac and its generic versions off the market.

In April 2024, one month prior to Pfizer’s settlement, Sanofi agreed to pay $100 million to 4,000 claimants who had filed lawsuits saying that the company deliberately failed to inform people that Zantac contained cancer-causing compounds.

Sanofi said that the allegations were false but that it decided to settle in order to avoid the costs of litigation.

Pfizer’s settlement involving the Zantac lawsuits was disclosed in a court filing in Delaware and is aimed at significantly reducing the company’s potential liability.

Pfizer has to pay plaintiffs $200 millions to $250 million to settle the cases. There have been 70,000 cases filed in Delaware state court against multiple drug makers and a few cases in California, Illinois and Pennsylvania.

Pfizer sold Zantac between 1998 and 2006 and said that the allegations are false and are not supported by “reliable science.” In a statement Pfizer defended the safety of Zantac:

The company is confident that its Zantac products, which were reviewed and approved by the [U.S. Food and Drug Administration], did not cause cancer when used as directed.

Zantac is back on the market with a new name, Zantac 360, and with an active ingredient, famotidine, that does not contain ranitidine.

LInk to article here.

Visit The Sharyl Attkisson Store today

Shop Now

Unique gifts for independent thinkers

Proceeds benefit independent journalism

Leave a Comment

Your email address will not be published. Required fields are marked *

2 thoughts on “Pfizer settles Zantac cancer lawsuits for $250 million”

  1. It’s beyond me why people think they need any over-the-counter drugs. There is even less honesty and truth being told by these drug manufacturers. Maybe even less CDC control, it’s what a manufacturer will tell them. If you have a back pain, sore muscles, headache just lie down and relax. If your retired, slow down and treat your body kindly. All you need, as a reminder, just listen to the advertising of drugs on national news about the many side effects that “may” kill you. Take care of your body, eat healthy, think positive and your own body has what it needs to keep you healthy.

  2. So I guess we can see that big pharma does in fact operate under the oath of “net present value”. That value just put each of the claimants lives at the value of $25k. Unreal & criminal.

Scroll to Top